Price (GBX)
103.00 -% (-)
ARIXORD 0.001P
Track 1 instrument
Open / Last close
- / 103.00
High / Low
105.00 / 103.00
Bid / Offer
100.00 / 106.00
Turnover
-
Special Condition: -
Trading Status: Market Close
As at 24.09.20 00:16:46 - All data delayed at least 15 minutes

Arix Bioscience PLC instruments

Select instrument to view
Equity (1)
Code Instrument name Price Change Type Documentation
ARIXORD 0.001P103.00
GBX
-Equity-

Price information

What's this?
Open price
-
Previous close price / date
103.00 / 24 September 2020
Volume
227,962
Turnover
-
52 week range
58.50 / 121.00
YTD return
-3.29
1 year return
-10.82

Instrument information

What's this?
Market
Main Market
Instrument market cap (£m)
139.68
Earnings per share
-0.54
Issue date
17 February 2017
ISIN
GB00BD045071
SEDOL
BD04507
Market identifier code (MIC)
XLON
Country of share register
GB
Market segment
SSQ3
Trading service
SETSqx
Date Time Price CurrencyVolume Trade ValueTrade type Trade flag MIC
24.09.20 16:44:37 104.00 GBX 100,000 104,000.00 Off-Book - SINT
24.09.20 16:24:05 104.00 GBX 100,000 104,000.00 Off-Book - SINT
24.09.20 15:59:29 102.50 GBX 22,200 22,755.00 Off-Book - XLON
24.09.20 14:43:15 101.00 GBX 496 500.96 Off-Book - XLON
24.09.20 14:29:55 101.00 GBX 2,500 2,525.00 Off-Book - XLON

Equity Research

from Arix Bioscience PLC
Realising the valuation disconnect

Arix Bioscience (ARIX) is a listed global venture capital (VC) company that presents an opportunity for institutional and retail investors to participate in the high risk-return profile of early-stage biotech investing. ARIX minimises risk through its expert investment team and with portfolio div ...

View report
THE MONTHLY September 2020

The COVID-19 pandemic has had a significant impact globally in many areas. While primarily a health issue, it has had wide-ranging implications for stock markets, which have now rallied after the plunge in share prices in mid-March when the full severity of the emerging pandemic became more widel ...

View report
THE MONTHLY August 2020

For this Monthly, we are delighted that Rooney Nimmo and 24Haymarket have allowed us to reproduce a recent report they jointly published, entitled An analysis of UK exits (2015-2019), which provides a granular analysis by sector of the activity in our dynamic private companies world. We hope you ...

View report
THE MONTHLY July 2020

A number of REITs have the ability to thrive in current market conditions and thereafter. Not only do they hold assets that will remain in strong demand, but they have focus and transparency. The leases and underlying rents are structured in a manner to provide long visibility, growth and securit ...

View report
The Monthly June 2020

Much has been written about the effects of the virus on the world and on the stock market. Here is one analyst’s take on some of the likely impacts on the way we should look at companies. This article was originally produced as a blog, “10 Changes Post Virus”, which was publishe ...

View report

Latest reports

from Arix Bioscience PLC
Annual Report 2018
link

Contacts

from Arix Bioscience PLC
Head of Investor Relations
Charlotte Parry
atArix Bioscience PLC
0207 2901050
ir@arixbioscience.com
Issuer presentations live and on demand
Watch on Spark Live